Video

What Are the Current Treatment Options in Lung Cancer?

Sandip Patel, MD, an associate professor of medical oncology at University of California San Diego, explains the optimal diagnostic strategies that can be utilized to better inform biomarker-based therapies in lung cancer.

Sandip Patel, MD, an associate professor of medical oncology at University of California San Diego, explains the optimal diagnostic strategies that can be utilized to better inform biomarker-based therapies in lung cancer.

Related Videos
Ewa Kalinka, MD, PhD
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Sandip P. Patel, MD
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Related Content
Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Alison Schram, MD
January 16th 2025

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

NSCLC | © catalin | stock.adobe.com
January 14th 2025

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC

FDA
January 13th 2025

Dato-DXd Receives FDA Priority Review in Pretreated EGFR-Mutated NSCLC